Gout patients frequently have a number of comorbidities, including obesity, hypertension, high serum lipid and cholesterol levels, kidney disease, diabetes, and cardiovascular disease. [2,7,19–21] Due ...
SAN DIEGO, March 5, 2025 /PRNewswire/ — Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 ...
WATERTOWN, Mass. and STOCKHOLM, March 21, 2023/ PRNewswire/-- Selecta Biosciences, Inc. and Sobi ®, today announced positive topline results from the Phase 3 DISSOLVE I& II placebo controlled ...
STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE I, ...
STOCKHOLM and WATERTOWN, Mass., Sept. 23, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commencement of ...
Please provide your email address to receive an email when new articles are posted on . Both excessive and long-term alcohol consumption, as well as any spirit consumption, predict the development of ...
DISSOLVE clinical program The Phase 3 DISSOLVE clinical program consisted of two double-blind, placebo-controlled studies of SEL-212, titled “A Randomized Double-Blind, Placebo-Controlled Study of SEL ...
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results